Hybridan Small Cap Feast: 03/04/2024

* A corporate client of Hybridan LLP

** Arranged by type of listing and date of announcement

*** Alphabetically arranged

**** Potential means Intention to Float (ITF) has been announced

Dish of the day

Admissions:   

 None

Delistings: 

600 Group Plc (SIXH.L) has left AIM

What’s baking in the oven? **

Potential****  Initial Public Offerings:

21 March 2024: Helix Exploration is pursuing the exploration, commercial development and monetisation of a non-hydrocarbon associated helium rich gas structure in the Ingomar Dome located in central Montana, USA. The Company announces its intention to list its shares on AIM. Total capital to be raised on Admission of up to £7.5m. Expected Admission date of early April 2024.

18 March 2024: European Green Transition is developing a portfolio of green economy assets in Europe which aims to capitalise on the opportunity created by the green energy transition announces its proposed Admission to trading on AIM and its successful placing and subscription at a price of 10p per Share with institutional and other investors.  The Company has raised approx. £6.45m. Admission is proposed for 8 April.

Reverse Takeovers:

 None

Change of Market:

None

Banquet Buffet***

 Cleantech Lithium  14.75p £21.4m (CTL.L) Follow | CTL

The exploration and development company advancing lithium projects in Chile, following a meeting with representatives of Chile´s Mining Ministry last week, will be resubmitting the applications for Special Lithium Operating Contracts (CEOLs) for Laguna Verde and Francisco Basin by updating them in line with the latest requirements. The resubmission process has no impact on the expected project timeline. This follows the Chilean Government outlining a new process for private companies to express interest to develop non-strategic salars for lithium production in Chile starting from April 2024.

Comptoir  6.75p £8.3m (COM.L) Follow | COM

The owner and/or operator of Lebanese, Middle Eastern and North African inspired restaurants announces the appointment of James Fisher as Finance Director.  James, who joins from Wahaca, will start at Comptoir in Summer 2024 and will be appointed to the Board. James brings more than a decade of experience in senior financial roles across the consumer and hospitality sectors.

Corero Network Security  10.1p £51.4m (CNS.L) Follow | CNS

The Company focusing on Distributed Denial of Service (DDoS) protection solutions, announces a contract renewal and expansion with a US Software-as-a-Service provider. The Contract, valued at over $2m over three years, enables Corero to expand the customer's existing DDoS protection infrastructure to support its continued international growth. The Company continue to explore new business and mandate expansion opportunities.

Croma Security Solutions Group  68.5p £9.4m (CSSG.L) Follow | CSSG

The innovation and service-focused security solutions provider announces the award of a new NHS Trust contract worth approximately £0.4m to be completed in the current financial year, ending 30 June 2024. The contract relates to the installation of new security systems across the hospitals. Croma already operates a number of other existing smaller security projects with the NHS Trust, and believes there is potential for further projects.

Crossword Cybersecurity*  4.25p £4.3m (CCS.L) Follow | CCS

The cybersecurity solutions company focused on cyber strategy and risk, announces the appointment of Stuart Jubb to the board of the Company as executive director with immediate effect. Stuart joined Crossword in February 2016 to head up Crossword's newly established cybersecurity consulting division.  From 1 January 2022, Stuart has been Group Managing Director of Crossword, with responsibility for Consulting, Sales and Managed Services, and in September 2023 also became responsible for Product.

Genedrive  5.25p £7.3m (GDR.L) Follow | GDR

The point of care pharmacogenetic testing company, announces that the UK's National Institute for Health and Care Excellence (NICE) has recommended in draft guidance that the Genedrive® CYP2C19-ID test should be used as the point-of-care (POC) test of choice before clopidogrel administration in the management of Ischemic Stroke and Transient Ischaemic Attack patients. The decision was based on several differentiating features including; (1) its greater coverage of genetic variants, (2) no requirement for cold-chain storage logistics, (3) its ability to integrate with patient electronic healthcare systems.

Oxford Biodynamics  9.8p £19.8m (OBD.L) Follow | OBD

The biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the completion of the clinical validation of its EpiSwitch Prostate Screening (PSE) test at the Company's newly commissioned ISO15189 UK clinical laboratory. The launch will cut in half the turnaround time for any PSE tests ordered by UK physicians. OBD will soon begin validating its other marketed precision medicine clinical test, the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) within this new UK facility. 

Shearwater Group  43.5p £10.4m (SWG.L) Follow | SWG

The cybersecurity, advisory and managed security services group, announces a trading update for the financial year ended 31 March 2024 (FY24). Revenue in FY24 is expected to be c.£22.5m (FY23: £26.7m), with adjusted EBITDA at just under £1m (FY23: £(0.2)m). The cash position at the financial year end wast £5m. The Group further announces post period that their first scheduled contract renewal is secured to a value of £1.4m and has been signed with a British media and telecommunications company. The Company is trading in line with expectations.

Spectra Systems Corporation  218p £104.6m (SPSY.L) Follow | SPSY

The company focusing in machine-readable high speed banknote authentication, brand protection technologies announces the world's first polymer banknote substrate that is part of a mass-balanced recycling supply chain certified by the International Sustainability and Carbon Certification (ISCC) PLUS process. The use of Certified-Circular Polymer based on advanced recycling of plastics, has many points of environmental impacts including using plastic waste as an alternative to fossil fuels and additional end of life options for plastic waste.

Trakm8 Holdings  8.75p £4.4m (TRAK.L) Follow | TRAK

The telematics and data insight provider provides the following update. Post period operational cash generation for the Period is expected to be £5.4m (FY-2023: £4.3m). In addition, cash on hand amounted to £1.4m (FY-2023: £1.1m) and net debt was £4.9m (FY-2023: £5.6m). The Group also has an unused overdraft facility of £0.5m. The Company further announces that, on 2 April 2024, the Group completed the purchase Intellectual Property from Action 365 Limited, under a software licence agreement, for a total consideration of £500k.

 Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.